Trimodal organ‑preserving treatment of muscle‑invasive bladder cancer
Open Access
- 26 March 2023
- journal article
- review article
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (1) , 111-125
Abstract
Purpose of the study. Generalization of the world experience of organ‑preserving treatment in muscle‑invasive bladder cancerMaterials and methods. The literature was searched in Medline, Cochrane Library, Elibrary and PubMed systems. Publications describing the modern possibilities of organ‑preserving treatment of muscle‑invasive bladder cancer were included, 58 of which were used to write this review.Results. The review highlights the results of international randomized and significant non‑randomized studies of organ‑preserving treatment in muscle‑invasive bladder cancer. Special attention is paid to the description of a modern combination of treatment methods to achieve its maximum effectiveness while maintaining the quality of life of patients. The analysis of the world literature was carried out, confirming the prospects of organ‑preserving treatment with careful selection of patients.Conclusion. Organ-preserving trimodal therapy for muscle‑invasive bladder cancer remains an alternative treatment strategy. Careful selection of patients plays a key role. The modern approach to trimodal therapy (TMT) is as follows: complete transurethral resection of the bladder (TURB), neoadjuvant or adjuvant chemotherapy, subsequent assessment of the response to treatment (re‑staging with TURB) should be performed; with a complete pathomorphological response, a course of remote radiation therapy up to TFD 60–66 Gy in the case of traditional fractionation (focal radiation therapy and the use of hypofractionation modes are also possible), using modern irradiation technologies (IGRT, IMRT). In case of an incomplete response, the implementation of the radical cystectomy (RCE) is shown. If a relapse occurs during follow‑up after treatment in the volume of TMT, a life‑saving RCE is shown.If the above conditions are met, the oncological results of treatment with TMT are equivalent to those during RCE, but require further study.Keywords
This publication has 50 references indexed in Scilit:
- Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Bladder preservation in the treatment of muscle‐invasive bladder cancer ( MIBC ): a review of the literature and a practical approach to therapyBJU International, 2013
- Upper urinary tract recurrence after radical cystectomy for bladder cancer: Incidence and risk factorsInternational Journal of Urology, 2011
- Long-Term Complications of Conduit Urinary DiversionJournal of Urology, 2011
- Treatment of Muscle Invasive Bladder Cancer: Evidence From the National Cancer Database, 2003 to 2007Journal of Urology, 2011
- Differential Complication Rates Following Radical Cystectomy in the Irradiated and Nonirradiated PelvisEuropean Urology, 2010
- Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06Journal of Clinical Oncology, 2009
- Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survivalCancer, 2005
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003
- Long-Term Followup of all Patients with Muscle Invasive (Stages T2, T3 and T4) Bladder Carcinoma in a Geographical RegionJournal of Urology, 1997